These are useful in the treatment of cognitive impairment associated with neurodegenerative disorders
Suven Life Sciences has been granted one product patent from Europe (2758394) and one product patent from Hong Kong (1173140) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, parkinson and schizophrenia.
With these new patents, Suven has a total of 16 granted patents from Europe and 17 product patents from Hong Kong. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.